MISSISSAUGA, ON, Jan. 14, 2022 /CNW/ - Covalon Technologies Ltd.
(the "Company" or "Covalon") (TSXV: COV) (OTCQX: CVALF), an
advanced medical technologies company, today announced that it has
appointed Jason F. Gorel as its
interim Chief Financial Officer. Mr. Gorel has been appointed
interim Chief Financial Officer while the Company undertakes a
search for a new Chief Financial Officer to assist Covalon with its
next phase of growth.
"Jason brings financial leadership skills, operational
experience, and knowledge of asset management and information
systems to Covalon," said Brian
Pedlar, Chief Executive Officer of Covalon. "We look forward
to his contribution to our Company."
Mr. Gorel has more than 20 years of senior financial leadership
experience in both the private and public sectors. Mr. Gorel has
been Chief Financial Officer of several companies, including
Toronto Community Housing Corporation and BCS Global Networks Inc.
Mr. Gorel has held senior finance positions with SmartCentres Real
Estate Investment Trust and Canadian Apartment Properties Real
Estate Investment Trust. Mr. Gorel also serves on the Board of
Directors of Fairplay Ventures Inc., a publicly listed capital pool
corporation on the TSX Venture Exchange, and has served on the
Board of Directors of the Hearing Foundation of Canada.
Mr. Gorel carries the designations of Chartered Financial
Analyst, Chartered Professional Accountant (Chartered Accountant),
and Certified Public Accountant (Illinois). He has also completed the Director
Education Program at the Institute of Corporate Directors through
the University of Toronto's
Rotman School of Management.
About Covalon
Covalon Technologies Ltd. is a
researcher, developer, manufacturer, and marketer of
patent-protected medical products that improve patient outcomes and
save lives in the areas of advanced wound care, infection
management and surgical procedures. Covalon leverages its patented
medical technology platforms and expertise in two ways: (i) by
developing products that are sold under Covalon's name; and (ii) by
developing and commercializing medical products for other medical
companies under development and license contracts. The Company is
listed on the TSX Venture Exchange, having the symbol COV and
trades on the OTQX Market under the symbol CVALF. To learn more
about Covalon, visit our website at www.covalon.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release contains forward-looking statements which
reflect the Company's current expectations regarding future events.
The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend" and statements that an event or
result "may", "will", "should", "could" or "might" occur or be
achieved and other similar expressions. These forward-looking
statements involve risk and uncertainties, including the difficulty
in predicting product approvals, acceptance of and demands for new
products, the impact of the products and pricing strategies of
competitors, delays in developing and launching new products, the
regulatory environment, fluctuations in operating results, the
impact and timing of COVID-19 on operating activities and market
conditions, and other risks, any of which could cause
results, performance, or achievements to differ materially from the
results discussed or implied in the forward-looking statements.
Many risks are inherent in the industry; others are more specific
to the Company. Investors should consult the Company's ongoing
quarterly filings for additional information on risks and
uncertainties relating to these forward-looking statements.
Investors should not place undue reliance on any forward-looking
statements. The Company assumes no obligation to update or alter
any forward-looking statements whether as a result of new
information, further events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/covalon-announces-appointment-of-interim-cfo-301460977.html
SOURCE Covalon Technologies Ltd.